#USA #San Francisco #Securities Class Action #Hagens Berman #Corcept Therapeutics

Investors Alert: Corcept Therapeutics Faces Class Action Lawsuit

In a shocking turn of events for investors of Corcept Therapeutics Incorporated (NASDAQ: CORT), national shareholder rights law firm Hagens Berman has announced a class action lawsuit targeting the company. This comes after the FDA’s rejection of Corcept's primary drug candidate and significant patent challenges faced in federal court. The firm has urged affected investors to take action, emphasizing that the deadline to apply as a Lead Plaintiff in this ongoing litigation is April 21, 2026.

The Background of the Lawsuit

The lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., has been filed in the U.S. District Court for the Northern District of California. It aims to recover losses for all stakeholders who purchased Corcept common stock during the specified Class Period from October 31, 2024, to December 30, 2025. Investors are strongly encouraged to visit Hagens Berman's official CORT Case Page to gain insight into the allegations and necessary actions they should consider.

Key Allegations Against Corcept

One of the central claims made in the lawsuit revolves around the failure to disclose critical FDA warnings regarding the efficacy of its lead drug candidate, relacorilant. Specifically, the complaint alleges that Corcept management consistently conveyed a misleading narrative about the drug's readiness, despite documented shortcomings in clinical data highlighted by the FDA during preparatory meetings in early 2025.

The CRL Bombshell

On December 31, 2025, Corcept's predicament escalated dramatically when the company revealed it had received a Complete Response Letter (CRL) from the FDA. The CRL indicated that the agency could not endorse relacorilant due to inadequate evidence to support its safety and effectiveness — prompting a staggering 50% drop in the company's stock price, from $70.20 to $34.80. This drastic change wiped out about $2.5 billion in market capitalization in mere hours, leaving many investors reeling from their losses.

Taking Action

Hagens Berman has made it clear that investors who believe they have incurred significant losses due to Corcept's actions must act swiftly. The firm is facilitating communication for those wishing to be appointed as Lead Plaintiff by the April deadline, informing them it is imperative to document their experiences in light of the allegations.

For those wanting more information, Reed Kathrein at Hagens Berman is handling communications and can be reached directly at 844-916-0895 or via email at [email protected].

Whistleblower Opportunities

Furthermore, individuals with non-public information related to Corcept may also have avenues for involvement in the ongoing investigation. Under the SEC Whistleblower program, tips that yield a successful recovery could lead to substantial rewards, amounting to up to 30% of the recovery amount.

About Hagens Berman

Hagens Berman is a noted global law firm advocating for plaintiffs in complex litigation cases. They are committed to holding corporations accountable while securing substantial settlements for those impacted by misleading practices and negligence. The firm boasts an impressive track record, having recovered over $2.9 billion for investors and other clients over the years. More information can be found by following them on their social media platforms or visiting their website.

In these uncertain times for Corcept investors, proactive engagement and informed decision-making will be essential to navigate the legal complexities that lie ahead.

Stay alert, and ensure you are fully informed by visiting Hagens Berman's resources regarding this evolving situation.